Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

被引：1
|
作者：
Gunaratne, Ruwan [1 ,2 ]
Zhou, Crystal [1 ]
Tai, Jesse W. [1 ]
Schwede, Matthew [1 ]
Tanaka, Kailee [1 ]
Alkaitis, Matthew [3 ]
Yin, Raymond [4 ]
Sworder, Brian J.
Mannis, Gabriel [1 ,5 ]
Majeti, Ravindra [1 ,6 ]
Khodadoust, Michael S. [8 ,9 ]
Kurtz, David M. [1 ,2 ,7 ]
Zhang, Tian Y. [1 ,7 ]
机构：
[1] Stanford Univ, Div Hematol, Dept Med, Stanford, CA USA
[2] Stanford Univ, Div Oncol, Dept Med, Stanford, CA USA
[3] Stanford Univ, Dept Med, Stanford, CA USA
[4] Univ Calif San Francisco, San Francisco, CA USA
[5] Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA USA
[6] Stanford Univ, Stanford Inst Stem Cell Biol & Regenerat Med, Stanford, CA USA
[7] Stanford Canc Inst, Stanford, CA USA
[8] Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA USA
[9] Stanford Univ, Sch Med, Dept Med Oncol, Stanford, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] CLINICAL IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA (AML)
    Venditti, A.
    Buzzatti, E.
    Guarnera, L.
    Bonanni, F.
    Moretti, F.
    Pascale, M. R.
    Mallegni, F.
    Palmieri, R.
    Paterno, G.
    Del Principe, M. I.
    Maurillo, L.
    Voso, M. T.
    Buccisano, F.
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 202 - 205
  • [2] Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
    Tiong, Ing S.
    Loo, Sun
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [3] Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
    Patricia Simoes, Catia
    Villar, Sara
    Ariceta, Benat
    Garces, Juan-Jose
    Burgos, Leire
    Alignani, Diego
    Sarai, Sarvide
    Martinez-Cuadron, David
    Bergua Burgues, Juan Miguel
    Vives, Susana
    Algarra, Lorenzo
    Tormo, Mar
    Martinez Sanchez, Pilar
    Serrano, Josefina
    Herrera, Pilar
    Ramos, Fernando
    Salamero, Olga
    Lavilla, Esperanza
    Gil, Cristina
    Lopez Lorenzo, Jose Luiz
    Belen Vidriales, Maria
    Chillon Santos, Maria Carmen
    Labrador, Jorge
    Falantes, Jose F.
    Jose Sayas, Maria
    Ayala, Rosa
    Martinez-Lopez, Joaquin
    Alfonso-Pierola, Ana
    Jose Calasanz, Maria
    Prosper, Felipe
    San-Miguel, Jesus
    Sanz, Miguel A.
    Montesinos, Pau
    Paiva, Bruno
    [J]. BLOOD, 2022, 140 : 2270 - 2272
  • [4] Novel Circulating Tumor Dna (CTDNA) Based Ddpcr Drop-OFF Assays for Improved Minimal Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML)
    Rausch, Christian
    Ziemann, Frank
    Schneider, Stephanie
    Subklewe, Marion
    Spiekermann, Karsten
    Thorley, Maja Rothenberg
    Metzeler, Klaus
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 107 - 107
  • [5] Novel circulating tumor DNA (ctDNA) based ddPCR drop-off assays for improved Minimal Residual Disease (MRD) monitoring in Acute Myeloid Leukemia (AML)
    Rausch, C.
    Ziemann, F.
    Schneider, S.
    Subklewe, M.
    Spiekermann, K.
    Rothenberg-Thurley, M.
    Metzeler, K. H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 252 - 252
  • [6] Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
    Re-I Chin
    Kevin Chen
    Abul Usmani
    Chanelle Chua
    Peter K. Harris
    Michael S. Binkley
    Tej D. Azad
    Jonathan C. Dudley
    Aadel A. Chaudhuri
    [J]. Molecular Diagnosis & Therapy, 2019, 23 : 311 - 331
  • [7] Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA)
    Chin, Re-I
    Chen, Kevin
    Usmani, Abul
    Chua, Chanelle
    Harris, Peter K.
    Binkley, Michael S.
    Azad, Tej D.
    Dudley, Jonathan C.
    Chaudhuri, Aadel A.
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2019, 23 (03) : 311 - 331
  • [8] Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Brooimans, Rik A.
    van der Velden, Vincent H. J.
    Boeckx, Nancy
    Slomp, Jennita
    Preijers, Frank
    te Marvelde, Jeroen G.
    Van, Ngoc M.
    Heijs, Antoinette
    Huys, Erik
    van der Holt, Bronno
    de Greef, Georgine E.
    Kelder, Angele
    Schuurhuis, Gerrit Jan
    [J]. LEUKEMIA RESEARCH, 2019, 76 : 39 - 47
  • [9] Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?
    Hochman, Michael Jamie
    Othus, Megan
    Shaw, Carole
    Gardner, Kelda
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Estey, Elihu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Measurable Residual Disease (MRD): Is it a Thing in AML?
    Ossenkoppele, Gert
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S59 - S60
12345